Portfolio

Pieris AG
www.pieris-ag.com 
Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins^®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

Affimed Therapeutics AG
www.affimed.com
Affimed is a private biopharmaceutical company based in Heidelberg, Germany specialising in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg. By utilizing its broad portfolio of proprietary, in-house technology platforms together with crucial enabling freedom-to-operate licenses, the company has been able to establish a pre-clinical product pipeline of promising novel product candidates mainly for indications in oncology and autoimmune diseases.

Xencor, Inc.
www.xencor.com
Xencor, Inc., engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform. The company is internally advancing both XPro™ protein therapeutic candidates and XmAb™ antibody drug candidates optimized for activity against biologically validated targets. Xencor's product development is led by a protein therapeutic drug candidate, XPro1595, for the treatment of arthritis and other rheumatic disorders and antibody candidates for the treatment of cancer. With multiple partners, such as industry leaders Genentech, Roche, Centocor and MedImmune, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. Xencor also develops therapeutic protein variants in collaboration with major pharmaceutical partners.

TransTechPharma Inc.
www.ttpharma.com
TransTech Pharma is a clinical-stage
pharmaceutical company focused on the
discovery, development, and commercialization
of small molecule and protein therapeutics to fill
unmet medical needs.
TransTech Pharma's integrated Translational TechnologyTM platform consists of PharmaChem SpaceTM, PharmaBio SpaceTM, rapid ligand synthesis, High throughput analysis and characterization, High throughput in vitro and in vivo testing and reiteration coupled with a fully integrated informatics system that together minimize manual tasks and reliance on manpower. Using this platform, TransTech Pharma is dedicated to rapid and cost-efficient development of drug candidates within a range of in-house and collaborative projects.

Transition Therapeutics Inc.
www.transitiontherapeutics.com
Transition Therapeutics Inc. is a publicly traded biopharmaceutical company (NASDAQ trade symbol TTHI, TSX symbol TTH) with a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications.
Using its proprietary technologies, Transition is focused on developing therapeutic innovations that inhibit the progression of diseases such as diabetes, Alzheimer's disease and hepatitis C as well as restore or normalize function.

Innate Pharma S.A.S.
www.innate-pharma.com
Innate Pharma S.A.S. is a French biopharmaceutical company specialised in cancer immuno-therapeutics with currently two products in Phase I of clinical development. It is the first company to develop immuno-modulating medications and cellular therapies targeting non-conventional lymphocytes. Alongside the equity investment,  Innate Pharma and Novo Nordisk A/S have in November 2003 entered a collaboration aiming at the generation of a new therapeutics class of immuno-modulatory antibodies targeting natural killer (NK) cells. NK cells are a subset of non-conventional lymphocytes involved in immune regulation, and exerting direct cytotoxicity towards a wide range of tumor targets. This novel therapeutics strategy has recently been validated in leukemia patients.